Navigation Links
NIDA supports development of combined anti-heroin and HIV vaccine
Date:7/25/2012

Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development. Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIV infection in those receiving the vaccine. Matyas will receive $1,000,000 per year for five years to support his research. He works at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, M.d. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced the award today.

"This highly innovative dual-vaccine model would simultaneously address the intertwined epidemics of heroin abuse and HIV," said NIDA Director Dr. Nora D. Volkow. "This is precisely the type of ground-breaking research NIDA's Avant-Garde program was designed to support. The implications for public health are enormous."

The proposal stems from an existing research collaboration between NIDA and the U.S. Military HIV Research Program, part of the WRAIR. In 2010, the two organizations entered into an agreement to create a combination anti-heroin/HIV vaccine. The goal was to build upon previous preclinical research indicating that hapten-based anti-drug vaccinesin which a small molecule chemically similar to a drug of abuse (hapten) is bound to a protein carrier to induce an immune responseshowed promise against a variety of abused drugs, including heroin. As a result of this collaboration, the heroin component of a combination anti-heroin/HIV vaccine has now been created and is ready for optimization and advanced preclinical testing.

This current grant award will support this next phase of research and development. The award will be administered through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and work done in collaboration with the U.S. Military HIV Research Program and NIDA.

"Heroin use is strongly associated with a high risk of HIV infection and represents an increasingly important worldwide health problem," stated Matyas. "The possibility of creating a combination heroin-HIV vaccine provides an important opportunity to address both a unique treatment for heroin abuse as well as continuing the quest to develop an effective preventive HIV vaccine."


'/>"/>

Contact: NIDA Press Team
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert  

Related medicine news :

1. Study Supports Value of Sigmoidoscopy, an Alternative to Colonoscopy
2. Study supports urate protection against Parkinsons disease, hints at novel mechanism
3. Dietary fiber alters gut bacteria, supports gastrointestinal health
4. Narconon Louisiana Supports United Nations International Day Against Drug Abuse and Illicit Trafficking
5. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
6. Kudos for 3 NJIT Enterprise Development Center high-tech companies
7. 2 repressor genes identified as essential for placental development
8. Louisiana Tech University professor earns NSF Early Career Development grant
9. Advanced genetic screening method may speed vaccine development
10. New biospecimens management system in development
11. Developmental Woes Common in Siblings of Children With Autism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIDA supports development of combined anti-heroin and HIV vaccine
(Date:1/15/2017)... ... January 15, 2017 , ... The JPR Group, a ... announce that it will be assisting HackensackUMC Mountainside with its public relations efforts, ... servicing all surrounding towns. The firm will be working closely with HackensackUMC Mountainside’s ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... NJ (PRWEB) , ... January 13, 2017 , ... ... sale companions, will be showcasing the next generation companion scanner and data collector at ... The new KDC270 has been created as an answer to the market’s need for ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... 2017 , ... MyGenetx, a molecular laboratory headquartered in middle Tennessee is proud ... Smith, RD, LD, will serve on the 2017 TBCC Board. , Kris ... and one year as Vice President. She will oversee the newly elected board of ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017  Rosen ... the filing of a class action lawsuit on behalf ... ALXN ) from February 10, 2014 through November ... to recover damages for Alexion investors under the federal ... action, go to http://rosenlegal.com/cases-991.html or call ...
(Date:1/13/2017)... , Jan. 13, 2017 Over the last 10 years ... rapidly (6% – 10% yoy) and are expected to deliver remarkable future ... region, followed by Thailand , the Philippines ... and Singapore .  A member of the G20 and ... almost 40% of the SEA,s economic output and the largest pharma manufacturing ...
(Date:1/13/2017)... -- ... Research and Markets has announced the addition of the ... offering. The disease is divided into two categories ... melanoma, which can be treated with surgery, and advanced melanoma, which ... therapy aiming to prevent disease re-occurrence, and advanced therapies aiming to ...
Breaking Medicine Technology: